Harmony Biosciences Holdings, Inc.
HRMY · Nasdaq · USD · Market cap $1.9B · 293 employees
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States.
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price32.59 USD at the 20 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 20 Nov 2026
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 1.09)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $61.88 to $66.22, base estimate $61.88 (screen dated 2026-11-20).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 1.09, read 2026-11-19
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Harmony Biosciences Holdings, Inc. holds its Distribution at $32.59. Consolidating, no directional conviction, held for 9 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 9 days |
| Price at the screen | $32.59 |
| Valuation | 10.93 trailing · 5.44 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 0.98 |
Five Screens: HRMY's Results
FAIL. Accounts receivable
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 12.87% | Below 33% | Pass |
| Interest-bearing cash | 8.42% | Below 33% | Pass |
| Receivables | 66.79% | Below 49% | Fail |
| Revenue purity | 2.52% | Below 5% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Harmony Biosciences Holdings,'s business is fine, but its receivables are about 67% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when HRMY's ethical verdict changes
Today HRMY does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 47% discount to our $61.88 fair value, 12.30% revenue growth.
USD, 2026-11-20 screen. A 47.3% under base.
Street: 12 covering, consensus Buy. Average target +52%.
Rare Disease Drugmaker Trades At A Steep Discount
A patient with narcolepsy who finally sleeps through the night thanks to one approved pill shows how focused biotechs can turn rare conditions into steady revenue. Harmony Biosciences already sells WAKIX at a 17 percent revenue growth rate, delivers 16 percent profit margins and posts 18 percent return on equity, all while clearing our ethical screen without issue. The forward price to earnings ratio of just 5.6 times leaves plenty of room before it matches the 43 dollar analyst median target.
Yet the moat remains unknown and the business sits in a sector where one regulatory setback or fresh competitor can erase years of progress. That combination explains the none rating despite the 59 percent gap between the current 33.77 dollar price and our fair value estimate. High volatility around single-product exposure keeps the overall risk elevated.
Analysis, not advice.
| Forward P/E | 5.4xcheap for a company growing this fast |
| Trailing P/E | 10.9xreasonably valued |
| EPS, trailing | 3.02 |
| EPS, forward | 6.06 |
| Revenue growth | +12.3%steady growth |
| Profit margin | 18.1%healthy profit margins |
| Return on equity | 18.7%a solid return on shareholder capital |
| FCF yield | 9.89% |
| Debt to equity | 0.14minimal debt: a conservative balance sheet |
| Current ratio | 3.44comfortably covers its short-term bills |
| Beta | 0.98steadier than the market |
| Short interest, float | 0.15% |
| 52-week range | 25.90 - 43.49 |
| Market cap | $1.9B |
| Employees | 293 |
HRMY-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from markdown to distribution since the last review.
Earnings landed in this window. Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- Harmony Biosciences (HRMY) Stock May Be Undervalued On Earnings Power Yahoo Finance · 14d ago
- HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth Yahoo Finance · 16d ago
- Harmony Biosciences Holdings, Inc. Q3 2026 Earnings Call Summary Yahoo Finance · 17d ago
- Harmony Biosciences (HRMY) Q3 2026 Earnings Call Transcript Yahoo Finance · 17d ago
- Harmony Biosciences Q3 Earnings Call Highlights Yahoo Finance · 17d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-16 | Budur Kumar | CHIEF MEDICAL OFFICER | S - Sale+OE | 38,452 | $1,655,416 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $30.18 | +18.5% | · | $1,185 | +18.5% |
| 2 months | $28.89 | +23.8% | · | $1,238 | +23.8% |
| 3 months | $27.79 | +28.7% | · | $1,287 | +28.7% |
| 6 months | $39.59 | -9.7% | · | $904 | -9.7% |
| 1 year | $35.85 | -0.2% | · | $998 | -0.2% |
| 2 years | $29.92 | +19.6% | · | $1,196 | +19.6% |
| 3 years | $34.95 | +2.4% | · | $1,024 | +2.4% |
| 5 years | $31.99 | +11.8% | · | $1,118 | +11.8% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever HRMY does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.